Corcept Therapeutics Inc last reported quarterly results on Nov 3, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $340.5 million (+64.0% year over year) and diluted EPS of $1.01. It usually reports 29–55 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 23, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Feb 24, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 29–55 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 3, 2026
34 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
340
+64.0%
|
127
+544.6%
|
1.01
+531.2%
|
|
Jul 29, 2026
29 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
256
+31.7%
|
43
+22.3%
|
0.36
+24.1%
|
|
Apr 30, 2026
30 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
165
+4.9%
|
-32
-254.6%
|
-0.30
-276.5%
|
|
Feb 24, 2026
55 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
202
+11.1%
|
24
-21.0%
|
0.20
-21.9%
|
|
Nov 4, 2025
35 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
208
+13.7%
|
20
-58.3%
|
0.16
-61.0%
|
|
Jul 31, 2025
31 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
194
+18.7%
|
35
-1.0%
|
0.29
-9.4%
|
|
May 5, 2025
35 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
157
+7.1%
|
21
-26.0%
|
0.17
-32.0%
|
|
Feb 26, 2025
57 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
182
+34.3%
|
31
-1.9%
|
0.26
-9.2%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CORT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Redwood City, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1088856
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.